Speakers credit tariffs with reviving U.S. manufacturing, cite Novartis investment

Unidentified Speaker 1 credited recent tariffs with rescuing a domestic rack and steel manufacturer that had declined around 2015, saying the company moved from layoffs to working 'round the clock' and now faces a 36-week lead time on orders. "I put on the tariffs, and now he's going round the clock, making the racks, making the steel," the speaker said.

Unidentified Speaker 2 called tariffs "a game changer," saying they have "really been a big big difference" for U.S. factories and manufacturers. The speakers asserted broad economic benefits: "You've got thousands of businesses all over the country," one said, adding that companies are hiring and struggling to find enough workers.

The speakers gave several quantitative claims. They said the company shipped roughly 150 truckloads, about 30,000 racks, and that production and shipping typically use "about 2 ships, about 4 to 6 months" depending on other orders. On pricing, Unidentified Speaker 1 said Chinese producers were "producing racks at $90 a piece" while the speaker's domestic cost was about $150, and that tariffs "leveled the playing field."

Unidentified Speaker 2 cited a specific private-sector example, saying, "I had Novartis come in yesterday, a big drug company. They're building 11 factories, 11 11 drug plants for prescription drugs in The United States. I said, why are you doing that? He said, 1 reason, tariffs." The speakers also said opponents had mounted legal challenges: "We have to be between the Supreme Court with China centric people suing us," one said.

The remarks in this transcript are claims made by unidentified speakers; the transcript does not include supporting documentation or named government officials providing corroboration. There was no formal vote or policy action recorded in the remarks. The most recent procedural development reported was the speakers' assertion that the tariff policy is facing lawsuits at the Supreme Court.

Next steps: the speech concluded with a call to defend tariffs legally; no formal agency action, date, or public record of the claimed Novartis investments or company figures was provided in the transcript.